Harvard Apparatus Regenerative Technology, INC 10-Q quarterly reports

Harvard Apparatus Regenerative Technology, Inc. reported Q2 2026 results, highlighting revenue growth but also significant operating losses and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern.

Harvard Apparatus Regenerative Technology reports significant revenue growth in its Consumer Health segment while facing ongoing challenges in its regenerative biotech operations, underscoring its need for continued financing.

Harvard Apparatus Regenerative Technology reported increased product revenue and a reduced net loss for Q3 and the first nine months of 2025, but faces substantial doubt about its ability to continue as a going concern without further financing.

Harvard Apparatus Regenerative Technology reported a narrower net loss in Q2 2025, driven by consumer health product sales, but faces substantial doubt about its ability to continue as a going concern without further capital.

Harvard Apparatus Regenerative Technology reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Harvard Apparatus Regenerative Technology reported its third quarter 2024 results, highlighting progress in clinical trials and growth in its consumer health products segment, while also noting ongoing financial challenges.

Harvard Apparatus Regenerative Technology reported its second quarter 2024 results, highlighting a decrease in operating expenses but also raising concerns about its ability to continue as a going concern due to substantial operating losses.

Harvard Apparatus Regenerative Technology reported its first quarter 2024 results, highlighting a net loss and ongoing concerns about its ability to continue as a going concern.